Montelukast; a new medication for pediatric asthma management

Journal of Pediatric Health Care

Volumn 12, Issue 6, 1998, Pages 324-328

  Stohlmeyer, Leslie A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 11544330479     PISSN: 08915245     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0891-5245(98)90145-6     Document Type: Article

References (17)

1. Abbott Laboratories, (1997). Product information: Zileuton. North Chicago, IL: Author.
2. Allen, D. B. (1998). Influence of inhaled corticosteroids on growth: a pediatric endocrinologist's perspective. Acta Paediatrica, 87, 123-129.
3. Bisgaard, H. (1997). Use of inhaled corticosteroids in pediatric asthma. Pediatric Pulmonology, 15, 27-33.
4. De Lepeleire, I., Reiss, T. F., Rochette, F., Botto, A., Zhang, J., Kundu, S., & Decramer, M. (1997). Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clinical Pharmacology and Therapeutics, 61, 83-92.
5. Goode, J. R., & Small, R. E. (1998). Leukotriene modifiers. Journal of the American Pharmaceutical Association, 38, 48-57.
6. Holland, S., Shahane, A., Rogers, J. D., Porras, A., Grasing, K., Lasseter, K., Pinto, M., Freeman, A., Gertz, B., & Amin, R. (1998). Metabolism of montelukast (M) is increased by multiple doses of phenobarbital (P). Clinical Pharmacology and Therapeutics, 63, 231.
7. Kelloway, J. S., Wyatt, R. A., & Adlis, S. A. (1994). Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Archives of Internal Medicine, 154, 1349-1352.
8. Kemp, J. P., Dockhorn, R. J., Shapiro, G.G., Nguyen, H. H., Guerreiro, D. A., Reiss, T. F., Friedman, B. S., & Knorr, B. A. (1997). Montelukast, a leukotriene receptor antagonist, inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children. The Journal of Allergy and Clinical Immunology, 99, S321.
9. Knorr, B., Matz, J., Bernstein, J. A., Nguyen, H., Seidenberg, B. C., Reiss, T. F., & Becker, A. (1998). Montelukast for chronic asthma in 6- to 14-year-old children. Journal of the American Medical Association, 279, 1181-1186.
10. Leff, J. A., Israel, E., Noonan, M. J., Finn, A. F., Godard, P., Lofdahl, C.G., Friedman, B.S., Connors, L., Weinland, D. E., Reiss, T. F., & Kundu, S. (1997). Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability. American Journal of Respiratory Critical Care Medicine, 155, A976.
11. Merck & Company, Inc. (1998). Product information: Montelukast. West Point, PA: Author.
12. Pedersen, S. (1997). What are the goals of treating pediatric asthma? Pediatric Pulmonology, 15, 22-26.
13. Sorkness, C. A. (1997). The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma. Pharmacatherapy, 17, 50S-54S.
14. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. (1997). National Asthma Education Program, Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. Rockville, MD: Author.
15. Wenzel, S. E. (1998). New approaches to antiinflammatory therapy for asthma. The American Journal of Medicine, 104, 287-300.
16. Wenzel, S. E. (1997). Arachidonic acid metabolites: Mediators of inflammation in asthma. Pharmacotherapy, 17, 35-125.
17. Zeneca Pharmaceuticals. (1997). Product information: Zafirlukast. Wilmington, DE: Author.